CompletedEUCTR 2004-001981-41
Bipolarity: Lithium/ANti-Convulsant Evaluation
This historical record does not confirm current site availability.
Historical research recordItaly
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Italy
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,064
- Sponsor
- UNIVERSITY OF OXFORD
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Italy
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2004-001981-41
- Official title
Show the full official title
Bipolar Affective disorder: Lithium/ANti-Convulsant Evaluation
Recruitment & locations
CompletedItaly
Registry details
Historical country statuses
- Italy — Completed
Questions about this study
Who is behind this study?
The study sponsor is UNIVERSITY OF OXFORD, a university.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2007-005959-42
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...
France, Austria, Czechia, + 6 others
CompletedEUCTR 2010-023623-26
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...
Bulgaria, Finland, Germany, + 3 others
CompletedEUCTR 2017-000918-36
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolarity type I
Austria, Bulgaria, Ireland, + 3 others